In 2018, TRAAP1, a French multicenter randomized trial, failed to demonstrate a reduction in PPH incidence after vaginal delivery in women receiving prophylactic tranexamic acid in addition to oxytocin [30]. The gene discussed is OXT; the disease is pulmonary arterial hypertension.